Objective: To establish the frequency of impulse control disorder (ICD) in idiopathic Parkinson’s disease (IPD) and analyze contributing factors.

Background: To establish the frequency of impulse control disorder (ICD) in idiopathic Parkinson’s disease (IPD) and analyze contributing factors.

Method: Within the Luxembourg cohort (Hipp et al., 2018), IPD patients were annually evaluated for the presence of ICD (score ≥ 1 on item 1.6 of the MDS-UPDRS I rating scale) and medication use and compared to age-matched healthy controls (HC). Calculations were done with the Mann-Whitney U Test.

Results: 1106 subjects were eligible for the study: 512 IPD patients with 1 to 3 visits (V1-V3) and 594 HC with 1 baseline visit. 50 IPD (9.7%) patients scored positive for ICD in contrast to 34 HC (5.7%) (p=0.01). Among 236 IPD patients without dopamine agonist (DA) use, only 13 (5.5%) scored positive for ICD, in contrast to 37 (13.1%) among 276 patients with use of DA (p=0.004). Male sex or concomitant use of amantadine did not influence the presence of ICD. Frequency of ICD increased from V1 to V3 (p = 0.005).

Conclusion: In this observational study, without recruitment bias of a tertiary care center and thus more representative for the general PD population, IPD patients without use of DA agonists show a frequency of ICD comparable to HC. Thus ICD risk is not disease-inherent, however frequency significantly increased with the use of DA. There is no protective effect of amantadine and no sex preference. Our study confirms and extends previous reports on ICD in IPD (Cormier-Dequaire et al., 2018). IPD patients should be informed about ICD risk before initiating DA treatment.

« Back to 2019 International Congress

MDS Abstracts - https://www.mdsabstracts.org/abstract/frequency-of-impulse-control-disorder-in-parkinsons-disease-insights-from-the-luxembourg-cohort/